Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765239 | 1.00 | DPP4 (0.44) | DPP4DPP7CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL24157448 | 1.00 | DPP4 (0.44) | DPP4DPP7CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL12765247 | 0.89 | ALDH1A1 (0.44) | DPP4DPP7CHRM2CHRM4CHRM1 | |
| SCHEMBL12765248 | 0.89 | ALDH1A1 (0.44) | DPP4DPP7CHRM2CHRM4CHRM1 | |
| SCHEMBL13119145 | 0.89 | ALDH1A1 (0.41) | DPP4CHRM2CHRM4CHRM1HRH2 | |
| SCHEMBL25738639 | 0.84 | ARG1 (0.38) | ARG1HRH2HRH1 | |
| SCHEMBL13188562 | 0.82 | CHRM2 (0.42) | DPP4DPP7CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL24456549 | 0.81 | ALDH1A1 (0.50) | DPP4DPP7ALDH1A1NPC1LMNA | |
| SCHEMBL24710038 | 0.81 | DPP4 (0.48) | DPP4DPP7CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL25202270 | 0.80 | DPP4 (0.40) | DPP4DPP7CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902203-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7807664-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807664-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLA PHARMA INC. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7538105-B2 | Anti-infective agents | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| US-7183271-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183271-B2 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | DPP4 708/4885DPP7 476/4885CYP3A4 581/4885 |
| US-20070167429-A1 | 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof | SLC5A1, SLC5A2, DPP4 | DPP4 3/4885DPP7 6/4885CYP3A4 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.